Pancreas after kidney transplantation, is it the time to overcome the stigma?

Abstract

AbstractBackgroundPancreas transplantation is the most effective treatment to improve quality of life and overcome complications in patients with end‐stage renal disease and diabetes mellitus. One of the main approaches for concurrent renal disease and diabetes mellitus which has been underutilized during the past decade is a pancreas transplant after kidney transplantation. Our study aimed to quantify outcomes following pancreas after kidney transplants (PAKs) in the United States from 2001 to 2020 with an emphasis on graft and patient survival.Methods and MaterialsA retrospective registry analysis was performed by accessing the OPTN/UNOS database for PAKs that were performed in the United States from January 2001 to April 2020. The study population was divided into two subgroups: patients receiving a pancreas transplant between 2001 and 2010 and those receiving a pancreas transplant between 2011 and 2020.ResultsThe study examined a total number of 3706 PAK recipients; patients who received a PAK from January 2001 through December 2010 (n = 2892) and those who received a PAK from January 2011 to April 2020 (n = 814). The selection process of transplant recipients did not drastically change throughout the 2001–2010 and 2011–2020 periods. Length of stay at the hospital after the transplantation improved significantly in the 2011–2020 group relative to the 2001–2010 group (8.48 vs. 10.08 days, mean, p < 0.01). Additionally, more transplantation with 4–6 human leukocyte antigen mismatch occurred in the 2011–2020 group than in the 2001–2010 group (80.6% vs. 71.4%, p < 0.01). The pancreas preservation time of 13.35 h in the 2001–2010 group decreased significantly to 11.17 h in the 2011–2020 group (p < 0.001). The mean donor's amylase and lipase also decreased significantly in the 2011–2020 cohort. Significant graft survival improvement was observed in the 2011–2020 group compared to the 2001–2010 group after a long‐term follow‐up (p < 0.001). The mean Calculated Pancreas Donor Risk Index was 1.08 for the 2001–2010 group and 0.99 for the 2011–2020 group with a significant difference (p < 0.001).ConclusionThe beneficial results and improved outcomes observed in PAK patients demonstrate the effectiveness of the operation for individuals in need of a pancreas transplant. PAKs can prove to be a meaningful solution to overcome long waiting times, decrease the donor‐recipient imbalance, expand the donor pool, and overcome the current underutilization in order to improve the short‐ and long‐term quality of life in the groups of interest.